Trial · NCT05636891
Registered outcomes12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 12 of 12
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | PK parameters comparison between NNG-DEPO and Aranesp®: Cmax | IV:Assessed predose and at 0.25; 0.5; 4;12;24;48;96;144;240;336 hours postdose/ SC: Assessed predose and at 4;12;24;48;96;144;240;336 hours postdose | Serum peak concentrations (Cmax) |
| Primary | PK parameters comparison between NNG-DEPO and Aranesp®: AUC(0, t) | IV:Assessed predose and at 0.25; 0.5; 4;12;24;48;96;144;240;336 hours postdose/ SC: Assessed predose and at 4;12;24;48;96;144;240;336 hours postdose | Area under the curve from 0 to t (AUC 0-t) |
| Secondary | PD parameters comparison between NNG-DEPO and Aranesp®: Cmax of reticulocytes | Assessed predose and at and at 24;48;96;144;240;336 hours postdose | Serum peak concentrations (Cmax) of reticulocytes |
| Secondary | PD parameters comparison between NNG-DEPO and Aranesp®: AUC(0, t) of reticulocytes | Assessed predose and at and at 24;48;96;144;240;336 hours postdose | Area under the curve from 0 to t (AUC 0-t) of reticulocytes |
| Secondary | PD parameters comparison between NNG-DEPO and Aranesp®: Tmax of reticulocytes | Assessed predose and at and at 24;48;96;144;240;336 hours postdose | Time for the drug to reach peak concentration (Tmax) of reticulocytes |
| Secondary | PK parameters comparison between NNG-DEPO and Aranesp®:Tmax | IV:Assessed predose and at 0.25; 0.5; 4;12;24;48;96;144;240;336 hours postdose/ SC: Assessed predose and at 4;12;24;48;96;144;240;336 hours postdose | Time for the drug to reach peak concentration (Tmax) |
| Secondary | PK parameters comparison between NNG-DEPO and Aranesp®: AUC(0,∞) | IV:Assessed predose and at 0.25; 0.5; 4;12;24;48;96;144;240;336 hours postdose/ SC: Assessed predose and at 4;12;24;48;96;144;240;336 hours postdose | Area under the curve from 0 to ∞ (AUC0-∞) |
| Secondary | PK parameters comparison between NNG-DEPO and Aranesp®:T1/2 | IV:Assessed predose and at 0.25; 0.5; 4;12;24;48;96;144;240;336 hours postdose/ SC: Assessed predose and at 4;12;24;48;96;144;240;336 hours postdose | Half-life (T1/2) |
| Secondary | PK parameters comparison between NNG-DEPO and Aranesp®: CL/F | IV:Assessed predose and at 0.25; 0.5; 4;12;24;48;96;144;240;336 hours postdose/ SC: Assessed predose and at 4;12;24;48;96;144;240;336 hours postdose | CL/F |
| Secondary | PK parameters comparison between NNG-DEPO and Aranesp®:Vz/F | IV:Assessed predose and at 0.25; 0.5; 4;12;24;48;96;144;240;336 hours postdose/ SC: Assessed predose and at 4;12;24;48;96;144;240;336 hours postdose | Vz/F |
| Secondary | PK parameters comparison between NNG-DEPO and Aranesp®: λz. | IV:Assessed predose and at 0.25; 0.5; 4;12;24;48;96;144;240;336 hours postdose/ SC: Assessed predose and at 4;12;24;48;96;144;240;336 hours postdose | λz. |
| Secondary | Proportion of the adverse events (AE) including physical examinations, vital signs, and clinical laboratory investigations. | Week 0 (Assessed predose)- Week 24] | Rate of AE and SAE occurence |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05636891/registered